ロード中...

Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells

BACKGROUND: Triple-negative breast cancer (TNBC) has aggressive progression with poor prognosis and ineffective treatments. Selumetinib is an allosteric, ATP-noncompetitive inhibitor of MEK1/2, which has benn known as effective antineoplastic drugs for several malignant tumors. We hypothesized that...

詳細記述

保存先:
書誌詳細
出版年:BMC Cancer
主要な著者: Zhou, Yan, Lin, Shuchen, Tseng, Kuo-Fu, Han, Kun, Wang, Yaling, Gan, Zhi-hua, Min, Da-liu, Hu, Hai-yan
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2016
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5073736/
https://ncbi.nlm.nih.gov/pubmed/27769200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2773-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!